Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | HTR2B | P41595 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CD44 | P16070 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16039618 | 0.98 | HTR2C (0.51) | HTR2CHTR2BHTR2APNMTKDM4E | |
| SCHEMBL5022472 | 0.86 | PNMT (0.59) | HTR2CHTR2BHTR2APNMTKDM4E | |
| SCHEMBL17585086 | 0.86 | HTR2C (0.43) | HTR2CHTR2BHTR2APNMTCD44 | |
| SCHEMBL17585084 | 0.86 | HTR2C (0.43) | HTR2CHTR2BHTR2APNMTCD44 | |
| SCHEMBL4969717 | 0.84 | KDM4E (0.43) | HTR2CHTR2BHTR2APNMTKDM4E | |
| SCHEMBL17585089 | 0.84 | DRD1 (0.42) | HTR2CHTR2BHTR2APNMTKDM4E | |
| SCHEMBL12682948 | 0.83 | HTR2C (0.53) | HTR2CHTR2BHTR2APNMTCD44 | |
| SCHEMBL17585087 | 0.82 | ACACB (0.41) | HTR2CHTR2BHTR2APNMT | |
| SCHEMBL17585085 | 0.82 | ACACB (0.43) | HTR2CHTR2BHTR2APNMTALDH1A1 | |
| SCHEMBL17583866 | 0.81 | HTR2C (0.51) | HTR2CHTR2BHTR2APNMTCD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9713615-B2 | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | REXAHN PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9713615-B2 | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | REXAHN PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9713615-B2 | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | REXAHN PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160136166-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | Ocuphire Pharma, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20160136166-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | Ocuphire Pharma, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20160136166-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | Ocuphire Pharma, Inc. | 2016-05-19 | — | — | US | disclosed |
| EP-2970203-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL) METHANONE COMPOUNDS AS CANCER CELL GROWTH INHIBITORS | Rexahn Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9193707-B2 | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | REXAHN PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193707-B2 | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | REXAHN PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193707-B2 | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | REXAHN PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20020032191-A1 | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | LOWE JOHN A (US) | 2002-03-14 | — | — | US | disclosed |
| US-6235750-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | PFIZER INC | 2001-05-22 | — | — | US | disclosed |
| CN-1239952-A | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | PFIZER (US) | 1999-12-29 | — | — | CN | disclosed |
| EP-0946512-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998024766-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| EP-0569380-B1 | ACRIDINE DERIVATIVES | GLAXO LAB SA (FR) | 1997-05-28 | — | — | EP | disclosed |
| US-5604237-A | IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT | LABORATOIRES GLAXO SA (FR) | 1997-02-18 | — | — | US | disclosed |
| EP-0569380-A1 | ACRIDINE DERIVATIVES. | GLAXO LAB SA (FR) | 1993-11-18 | — | — | EP | disclosed |
| WO-1992012132-A1 | ACRIDINE DERIVATIVES | LABORATOIRES GLAXO S.A. (FR) | 1992-07-23 | — | — | WO | disclosed |
| EP-0494623-A1 | Acridine derivatives | LABORATOIRES GLAXO SA (FR) | 1992-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032191-A1 | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | HTR2C 253/4885HTR2B 281/4885HTR2A 202/4885 |
| US-20160136166-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | HRAS, RECQL, CDK4 | HTR2C 270/4885HTR2B 790/4885HTR2A 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.